The benefit of insulin glargine 300 U/ml for specific groups of patients in the context of available data

Czech version

Authors: Peter Novodvorský ^1,2
Authors‘ workplace: metabolické centrum s. r. o., Trenčín ¹; Department of Oncology & Metabolism, Medical School, University of Sheffield, United Kingdom ²
Published in: Diab Obez 2020; 20(39): 28-34
Category:

Overview

Potreba iniciácie terapie inzulínom v určitej fáze diabetu 2. typu (DM2T) vyplýva z patofyziológie tohoto ochorenia. Otázka správnej indikácie a načasovania inzulínoterapie pri DM2T však zostáva pomerne kontroverznou témou. Táto práca predstavuje hlavné výsledky štúdie BRIGHT a následných subanalýz BRIGHT Renal a BRIGHT Elderly a analyzuje ich význam pre správnu voľbu inzulínového preparátu pri iniciácii inzulínoterapie u pacientov s DM2T s ohľadom na ich vek a pridružené komorbidity, akými sú napr. chronická obličková choroba.

Keywords:

basal insulin – chronic kidney disease – diabetic nephropathy – elderly people with diabetes – glargine 300 U/ml – hypoglycaemia – insulin degludec – nocturnal hypoglycaemia – type 2 diabetes (DM2T)

Sources

Lean ME, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391(10120): 541–551. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)33102–1>.
IDF Diabetes Atlas. 9th ed. International Diabetes Federation: Brussells, Belgium 2019. Dostupné z WWW: <http://www.diabetesatlas.org>.
Home P, Riddle M, Cefalu WT et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 2014; 37(6): 1499–1508. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–2743>.
Davies MJ, D’Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669–2701. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0033>.
Iqbal A, Novodvorsky P, Heller SR. Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. Diabetes Metab J 2018; 42(1): 3–18. Dostupné z DOI: <http://dx.doi.org/10.4093/dmj.2018.42.1.3> Erratum in Corrigendum: Table and Text Correction. Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. [Diabetes Metab J 2018].
Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab 2017; 19(1): 3–12. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12782>.
Ratner RE, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15(2): 175–184. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12032>.
Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17(9): 859–867. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12485>.
Lane W, Bailey TS, Gerety G et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients with Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA 2017; 318(1): 33–44. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2017.7115>.
Wysham C, Bhargava A, Chaykin L et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients with Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017; 318(1): 45–56. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2017.7117>.
Rosenstock J, Cheng A, Ritzel R et al. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care 2018; 41(10): 2147–2154. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–0559>.
Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol 2017; 13(7): 385–399. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2017.39>.
Kawaguchi Y, Sawa J, Hamai C et al. Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec. Diabetes Ther 2019; 10(4): 1535–1541. Dostupné z DOI: <http://dx.10.1007/s13300–019–0654-y>.
Mauricio D, Meneghini L, Seufert J et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab 2017; 19(8): 1155–1164. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12927>.
Frier BM, Landgraf W, Zhang M et al. Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. Diabetes Obes Metab 2018; 20(12): 2894–2898. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13450>.
Harris S, Berard L, Westerbacka J et al. Early hypoglycemia after initiation of second-generation basal insulin (BI) analogs: patient characteristics and clinical outcomes. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 1095-P. Dostupné z DOI: < https://doi.org/10.2337/db19–1095-P >.
Bailey RA, Wang Y, Zhu V et al. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014; 7: 415. Dostupné z DOI: <http://dx.doi.org/10.1186/1756–0500–7-415>.
Wu B, Bell K, Stanford A et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007–2012. BMJ Open Diabetes Res Care 2016; 4(1): e000154. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjdrc-2015–000154>.
Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351(13): 1285–1295. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa041365>.
Alsahli M, Gerich JE. Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc 2014; 89(11): 1564–1571. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2014.07.013>.
Sullivan SD, Bailey TS, Roussel R et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab 2018; 20(9): 2148–2158. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13345>.
Haluzík M, Phillis-Tsimikas A, Bosnyak Z et al. Differences in HbA1c lowering effect and hypoglycemia risk between Gla 300 and IDeg according to renal function in the BRIGHT Trial. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 146-OR. Dostupné z DOI: < https://doi.org/10.2337/db19–146-OR>.
Charbonnel B, Vanita RA, Westerbacka J et al. Differences in HbA1c reduction between insulin glargine 300 U/mL (Gla-300) and insulin degludec100 U/mL (IDeg-100) in adults ≥70 years of age with T2DM in the BRIGHT trial. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 131-LB. Dostupné z DOI: <https://doi.org/10.2337/db19–131-LB>.